Long-Term Adherence and Persistence to Low-Dose Aspirin for the Prevention of Cardiovascular Disease: A Population-Based Cohort Study

Table 1

Demographics and median observation time of the study cohorts.

Data source	Cohort	N	Mean age (SD), years	% female	Median observation time^∗ (IQR), years
IQVIA Germany disease analyzer	Primary CVD prevention	43,013	69.5 (12.7)	51	4.3 (2.4–6.8)
	Secondary CVD prevention	101,704	69.0 (12.3)	42	4.1 (2.4–6.5)
	Secondary CVD prevention DAPT^†	23,073	65.3 (12.3)	32	4.0 (2.4–6.2)
IMRD UK	Primary CVD prevention	72,496	65.0 (15.2)	49	4.8 (2.8–7.3)
	Secondary CVD prevention	118,411	65.5 (13.1)	45	4.4 (2.6–6.8)
	Secondary CVD prevention DAPT^†	27,648	63.1 (12.7)	31	4.1 (2.4–6.3)

^∗From the date of the first low-dose aspirin prescription (index date). ^†Started on DAPT. Abbreviations: CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; IMRD, IQVIA Medical Research Data; IQR, inter-quartile range; SD, standard deviation.